20-02-2014 дата публикации
Номер: US20140050692A1
The invention provides polymers and methods for the treatment of pain and inflammation. 1. A polyester comprising one or more groups of formula (I):{'br': None, '—C(═O)-A-C(═O)—O-L-O—\u2003\u2003(I)'}{'sub': 1', '8', '2', '10, 'wherein A is a C-Cmethylene chain that is covalently linked to one or more residues of a non-steroidal anti-inflammatory; and L is a C-Cbranched or straight chain alkyl.'}2. The polyester of claim 1 , wherein the C-Cmethylene chain is covalently linked to the one or more residues of the non-steroidal anti-inflammatory through an ester or amide linkage.3. The polyester of which comprises one or more groups of formula (Ia):{'br': None, 'sub': '1-8', '—C(═O)—[CH(B)]—C(═O)—O-L-O—\u2003\u2003(Ia)'}wherein each B is independently a residue of a non-steroidal anti-inflammatory.5. The polyester of wherein D is —O—.9. The polyester of which comprises 2-200 repeating groups of formula (II).10. The polyester of which comprises at least 2 claim 8 , 3 claim 8 , 4 claim 8 , 5 claim 8 , 6 claim 8 , 7 claim 8 , 8 claim 8 , or 9 repeating groups of formula (II).13. The polyester of wherein each non-steroidal anti-inflammatory agent is selected from ibuprofen claim 1 , naproxen claim 1 , fenoprofen claim 1 , ketoprofen claim 1 , flurbiprofen claim 1 , suprofen claim 1 , benoxaprofen claim 1 , indoprofen claim 1 , pirprofen claim 1 , carprofen claim 1 , loxoprofen claim 1 , pranoprofen claim 1 , alminoprofen claim 1 , salicylic acid claim 1 , diflunisal claim 1 , salsalate claim 1 , oxaprozin claim 1 , indomethacin claim 1 , sulindac claim 1 , etodolac claim 1 , ketorolac claim 1 , diclofenac claim 1 , piroxicam claim 1 , meloxicam claim 1 , tenoxican claim 1 , lornoxicam claim 1 , isoxicam claim 1 , mefenamic acid claim 1 , meclofenamic acid claim 1 , flufenamic acid claim 1 , tolfenamic acid claim 1 , lumiracoxib and licofelone.14. The polyester of claim 1 , wherein L is a C-Cstraight chain alkyl.15. The polyester of claim 14 , wherein L is a C-Cstraight ...
Подробнее